Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

NCT06970353 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation
Advanced PDTC or ATC With NRAS Mutation

Interventions

DRUG: Tunlametinib
DRUG: Tunlametinib+PD-1 mAb

Sponsor

Fudan University